Search clinical trials for: Dipeptidyl Peptidase 4 Inhibitor

Total 2683 results

Merck Sharp & Dohme LLC

Completed

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes Mellitus
Guangwei Li

Completed

Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

Insulin Resistance | Insulin Secretion

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Germany, Spain, United States, Canada, Taiwan, Korea, Republic of, Finland, Denmark, France, Japan, Philippines, Vietnam
Fourth People's Hospital of Shenyang

Completed

The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Januvia Re-examination Study (MK-0431-181)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Liver Insufficiency
AstraZeneca

Completed

Study of Multiple Doses of Saxagliptin (BMS-477118)

Type 2 Diabetes Mellitus
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Hepatic Insufficiency
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of
Lund University

Completed

Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion

Healthy | Type 2 Diabetes

Sweden
Institut National de la Santé Et de la Recherche...

Terminated

A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Hepatitis C

France
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
Novartis Pharmaceuticals

Completed

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy (FPG-VISIT)

Diabetes Mellitus Type 2

Germany
University of Oslo School of Pharmacy
Oslo University Hospital

Completed

Sitagliptin in Renal Transplant Recipients

Glucose Intolerance

Norway
Takeda

Completed

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

Diabetes Mellitus

United States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Poland, United Kingdom, Argentina, Dominican Republic
Kowa Research Institute, Inc.

Completed

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

Type 2 Diabetes

United States
Hannover Medical School

Unknown

Vascular Effects of Sitagliptin in Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
University of Colorado, Denver

Completed

Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes

Type 1 Diabetes

United States
Phenomix
Forest Laboratories

Terminated

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States, Russian Federation, Ukraine
University of Chicago
Eisai Inc.

Terminated

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Melanoma

United States
University of Colorado, Denver

Completed

Incretin Effect in People With Impaired Fasting Glucose (1651)

Obesity

United States
Profil Institut für Stoffwechselforschung GmbH
Merck Sharp & Dohme LLC

Completed

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Pharmacological Action

Germany
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Polycystic Ovary Syndrome

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin Add-on to Insulin Background Therapy

Diabetes Mellitus, Type 2

China
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2)

Diabetes Mellitus, Type 2 | Diabetes

India, Japan, Russian Federation, Spain, Sweden, Argentina, Hungary, Norway, South Africa, Turkey, Bulgaria, Romania, Thailand, Portugal, Hong Kong, Mexico, Ukraine, Czechia
University of Washington
Medtronic; Abbott; American Diabetes Association

Completed

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management (CANDY-CANE)

Chronic Kidney Diseases | Type 2 Diabetes

United States
Ingrid Jazet
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Brown Adipose Tissue (Sita01)

Neoplasms, Adipose Tissue

Netherlands
Washington University School of Medicine

Completed

Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation

Inflammation | Cardiovascular Disease | Macrophage Infiltration

United States
Merck Sharp & Dohme LLC

Terminated

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Diabetes Mellitus Non-insulin-dependent
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Argentina, Turkey, Canada, South Africa, Mexico
University Health Network, Toronto
Merck Frosst Canada Ltd.

Completed

Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

Hyperlipidemia

Canada
University of Zurich
European Foundation for the Study of Diabetes

Completed

Role of Interleukin-6 in Exercise (Exil-6)

Obesity | Diabetes Mellitus, Type 2

Switzerland
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
Medical University of Graz

Completed

Incretin Effect on the Immunological Phenotype

Type 1 Diabetes

Austria
Indiana University School of Medicine

Completed

Sitagliptin Umbilical Cord Blood Transplant Study

Lymphoma, Non-Hodgkin | Leukemia, Myeloid, Acute | Acute Lymphoblastic Leukemia | Myelodysplasia | Leukemia, Myelogenous, Chronic

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
LG Life Sciences

Completed

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (GUARD)

Type 2 DM Patients With Moderate or Severe Renal Impairment

Korea, Republic of
The Catholic University of Korea
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients (VARIABLE)

Type 2 Diabetes Mellitus
Beijing Chao Yang Hospital

Unknown

Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

Obesity | Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Diabetes Mellitus, Type 2
Charles Drew University of Medicine and Science
National Center for Research Resources (NCRR)

Completed

Sitagliptin in Combination With Metformin and Sulfonylurea

Type 2 Diabetes Mellitus

United States
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Eli Lilly and Company

Completed

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy

3

Subscribe